Previous reports of patients with Coronavirus disease 2019 (COVID-19) showed higher severity of disease in cancer patients, including the intubation rate \[[@CR1]\]. These series focused on those with symptoms from COVID-19 requiring hospitalization, with lung cancer being the most frequent malignancy \[[@CR1], [@CR2]\]. We report characteristics and outcomes of COVID-19 + patients with breast cancer (BC) at an academic center in New York City.

Methods {#Sec2}
=======

We collected demographic, treatment, and outcome data from established patients with stage I-IV BC at Columbia University Irving Medical Center (CUIMC) and COVID-19 + from 3/10/20 to 4/29/20 (data cut off). COVID-19 + was determined by reverse transcription-polymerase chain reaction (RT-PCR) by nasal swab and/or high clinical or radiographic suspicion. Initially, all outpatients with symptoms were referred to the emergency department (ED) for testing; however, outpatient testing, including at an ambulatory referral-based CUIMC fever clinic, was rapidly expanded with cobas® SARS-CoV-2 testing (Roche). This study was CUIMC Institutional Review Board approved.

Results {#Sec3}
=======

Of the 4515 COVID-19 + total patients at CUIMC, 27 (0.6%) were established patients with a history of BC (Table [1](#Tab1){ref-type="table"}). Twenty-six (96%) were female; 15 (56%) White, 6 (22%) Black, and 12 (44%) identified as Hispanic. The median age was 56 years (range: 32--87), median body mass index was 28.5 kg/m^2^ (range: 21--47), and 7 (26%) were current/former smokers. Co-morbidities included 15 (56%) with hypertension, 6 (22%) diabetes, and 6 (22%) pulmonary disease. The majority had stage I-III BC and 5 (19%) metastatic disease. In the 6 months prior to COVID-19 + , 16 (59%) received chemotherapy, 12 (44%) hormone therapy, 6 (22%) HER2-directed therapy, 1 (4%) checkpoint inhibitor, 6 (22%) breast surgery, and 2 (7%) radiation therapy. Prior to COVID-19 + , the last received therapy was chemotherapy for 14 patients \[52%, median: 12 days (range 7--749)\], 10 (37%) hormone therapy \[median: 1 day (range 1--81)\], and 3 (11%) HER2-directed antibodies without chemotherapy \[median: 21 days (range 20--34)\]. Treatment disruptions occurred in 20 patients (74%) due to COVID-19 +.Table 1Baseline demographics, treatments, and outcomes in COVID-19 + patients with a history of breast cancer (*n* = 27)Pt \#AgeGenderStageSmokerCo-morbidityLast treatmentTime from last treatment to COVID-19 + , daysCOVID-19 + determinationCOVID-19 RT-PCR test locationAdmittedTreatment disruptionAlive165FIIINeverHtnNab-paclitaxel7RT-PCREDNYY232FIVNeverN/ANab-paclitaxel/atezolizumab12RT-PCREDNYY339FIINeverN/AGoserelin/aromatase inhibitor1RT-PCROnc clinicNYY487MIIFormerCad, HtnCarboplatin/paclitaxel7Presumed (Imaging)N/ANNN568FINeverCad, PulmCytoxan/methotrexate/5-FU16RT-PCREDYYY641FIIINeverPulmGoserelin/aromatase inhibitor81RT-PCRFever clinicNYY762FINeverHtnPertuzumab/trastuzumab21RT-PCROnc clinicNYY854FIIFormerN/AAromatase inhibitor1RT-PCRFever clinicYYY946FIINeverN/ATrastuzumab/pertuzumab/goserelin/aromatase inhibitor20RT-PCRFever clinicNYY1080FIIIFormerHtn, PulmDoxorubicin/cyclophosphamide22RT-PCREDYYY1148FIINeverHtnTaxol56RT-PCRFever clinicNYY1254FINeverDM, HtnAromatase inhibitor1Presumed (symptoms)N/ANNY1349FINeverDM, Htn, PulmTamoxifen1RT-PCREDYNY1478FIINeverDM, HtnTaxotere/cytoxan11RT-PCREDNYY1546FIVNeverDMFulvestrant47RT-PCRFever clinicNYY1655FIVCurrentHtn, PulmNab-paclitaxel749Presumed (symptoms)N/ANNY1756FIINeverN/APaclitaxel7RT-PCROnc clinicNYY1862FINeverHtn, CadPaclitaxel/trastuzumab7RT-PCROnc clinicNYY1973FIVNeverDM, HtnOral selective estrogen receptor downregulator1RT-PCRFever clinicYYY2049FIICurrentN/ATaxotere/carboplatin/trastuzumab/pertuzumab8RT-PCRFever clinicNYY2179FIIFormerHtnPaclitaxel/trastuzumab9Presumed (symptoms)N/ANYY2247FIIINeverHtn, DMTrastuzumab34RT-PCRFever clinicNYY2358FIIFormerN/AAromatase inhibitor1RT-PCREDYNY2459FIINeverHtnAromatase inhibitor1RT-PCREDYNY2574FIINeverN/AAromatase inhibitor1Presumed (symptoms)N/ANNY2675FIVNeverHtn, PulmCarboplatin/etoposide19RT-PCROnc clinicNYY2751FIIINeverN/ACarboplatin21RT-PCROnc clinicNYY*Cad* coronary artery disease,*DM* diabetes mellitus,*ED* emergency department,*F* female,*HTN* hypertension,*M* male,*N* no,*N/A* not applicable,*Onc Clinic* oncology clinic,*Pulm* pulmonary disease,*RT-PCR* reverse transcription polymerase chain reaction (nasal swab),*Y* Yes

Most common symptoms were cough (70%), fever (52%), shortness of breath (52%), fatigue (30%), diarrhea (22%), and myalgia (19%), with 30% having ≥ 4 symptoms (Fig. [1](#Fig1){ref-type="fig"}). Twenty-two patients (81%) had COVID-19 + confirmation by RT-PCR, 4 (15%) presumed COVID-19 + per clinical symptoms, and 1 (4%) based on imaging and symptoms. Eight (30%) were initially tested in the ED, of whom 3 were not admitted. The majority were tested in the outpatient setting: ambulatory oncology clinic (6 patients; 22%) or CUIMC fever clinic (8 patients: 30%).Fig. 1**a** Percentage of COVID-19-related symptoms with which patients presented who had a history of stage I--IV breast cancer (*n* = 27). **b** Percentage of these patients who presented with 0, 1, 2, 3, or at least 4 COVID-19-related symptoms

Of the 7 patients requiring hospitalization (26%), 3 were non-Hispanic Black, 3 Hispanic White, and 1 non-Hispanic White. Two received recent chemotherapy without targeted agents for early stage BC and 5 single-agent hormone therapy (1 for metastatic disease). Five admitted patient had at least 1 co-morbid disease, and 3 were former smokers. Five admitted patients required supplemental oxygen, and none needed intensive care-level support, including intubation or dialysis. All were discharged from the hospital. With a median follow-up from COVID-19 + diagnosis of 26 days (range 1--38), all patients were alive, except for an 87-year-old male with coronary artery disease, hypertension, and former smoker who received taxane-based chemotherapy for stage II BC seven days before symptoms.

Discussion {#Sec4}
==========

In our racially/ethnically diverse population of 27 COVID-19 + patients with BC, the majority (74%) did not require hospitalization, and one male with multiple co-morbidities died. This is of interest, as COVID-19 + males have reported worse outcomes than females \[[@CR3]\]. While treatment disruptions occurred in most patients (74%), it is unknown whether this represents a deviation from other patients who develop infections on therapy. While larger series are needed to understand the impact of COVID-19 in patients with BC, these initial data are reassuring that a substantial number recover from their infection.
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